Aurinia Pharmaceuticals (AUPH) vs Septerna (SEPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Septerna (SEPN) has outperformed Aurinia Pharmaceuticals (AUPH) over the past year, gaining 51.1% versus a loss of 6.3%. Aurinia Pharmaceuticals is the larger company by market cap ($1.97 billion vs $1.84 billion), about 1.1 times the size, while Septerna is growing revenue faster (+4174.5% vs +20.4%). Aurinia Pharmaceuticals converts more of its revenue into profit, with a net margin of 101.5% versus -106.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | SEPN |
|---|---|---|
| Share price | $14.70 | $38.61 |
| Market cap | $1.97B | $1.84B |
| 1-day change | -1.28% | -1.51% |
| YTD return | -7.84% | +38.49% |
| 1-year return | -6.25% | +51.06% |
| 5-year return | -23.95% | — |
| P/E ratio (TTM) | 6.45 | — |
| Forward P/E | 12.67 | — |
| EPS (TTM) | $2.28 | $-1.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $283.06M | $45.95M |
| Revenue growth (YoY) | +20.38% | +4174.51% |
| Net income (latest FY) | $287.20M | $-48.88M |
| Gross margin | 88.46% | — |
| Operating margin | 37.06% | -148.63% |
| Net margin | 101.47% | -106.37% |
| 52-week high | $19.25 | $53.34 |
| 52-week low | $13.52 | $22.78 |
| Distance from 52-week high | -23.64% | -27.62% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +25.85% | +53.38% |
| Average volume | 858.74K | 383.96K |
| Shares outstanding | 134.00M | 47.55M |
| Employees | 128 | 134 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SEPN has outperformed AUPH by 57.3 percentage points over the past year.
- Aurinia Pharmaceuticals is more profitable, keeping 101.5 cents of every revenue dollar as net income versus -106.4 cents for Septerna.
- Septerna grew revenue faster in its latest fiscal year (+4174.51% vs +20.38%).
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 134 employees
AUPH vs SEPN FAQ
Which is bigger, Aurinia Pharmaceuticals or Septerna?
Aurinia Pharmaceuticals (AUPH) is larger, with a market capitalization of $1.97B compared with $1.84B for Septerna (SEPN).
Which stock has performed better over the past year, AUPH or SEPN?
SEPN returned +51.06% over the past 12 months, compared with -6.25% for AUPH (price return, excluding dividends). Past performance does not predict future results.
Are Aurinia Pharmaceuticals and Septerna in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.